[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiofrequency-catheter-ablation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiofrequency-catheter-ablation":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,71,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100639560","pulsed-field-ablation-outcomes-with-efficacy-and-randomization-in-atrial-fibrillation-power-af-100639560",false,"NCT07601763","Pulsed Field Ablation Outcomes With Efficacy and Randomization in Atrial Fibrillation (POWER-AF)","Pulsed Field Ablation for Atrial Fibrillation Including Posterior Wall and Linear Ablation: A Randomized Controlled Trial of Safety and Efficacy (POWER-AF)","POWER-AF","Inclusion Criteria:\n\n1. Atrial fibrillation patients who will accept catheter ablation.\n2. Age ≥ 18.\n3. Be capable of understanding and signing the informed consent form.\n\nExclusion Criteria:\n\n1. Have contraindications for catheter ablation (such as atrial thrombosis, decompensated heart failure, etc.)\n2. Have accepted catheter ablation before.\n3. Myocardial infarction, or any cardiac interventional\u002Fsurgery has been performed within 3 months.\n4. Had a stroke or transient ischemic attack within 6 months.\n5. Allergy to iodine contrast agents.\n6. Participate in clinical trials related to other drugs or devices.\n7. Pregnant women, lactating women, or women with plans to become pregnant shortly.\n8. Active stage of infection.\n9. Secondary atrial fibrillation, such as combined with rheumatic heart disease, hypertrophic cardiomyopathy, etc.\n10. Patients who do not agree to be enrolled or are unable to cooperate to complete the study","ALL","18 Years",{"count":20,"type":21},1574,"ESTIMATED","INTERVENTIONAL",[24],"NA","Atrial fibrillation (AF) is one of the most common arrhythmias in clinical practice. As of 2019, there were approximately 59.7 million patients with AF worldwide, including atrial flutter (AF). Atrial fibrillation can significantly increase the risks of stroke, thromboembolism and heart failure in patients, seriously affecting their quality of life.\n\nCatheter ablation is the main means for rhythm control in patients with atrial fibrillation. A large number of clinical studies have confirmed the effectiveness and safety of catheter ablation for atrial fibrillation. It is significantly superior to drug treatment in maintaining sinus rhythm and can significantly improve symptoms and quality of life.\n\nPulsed electric field ablation (PFA) is a novel ablation method that utilizes pulsed electric fields as energy. It uses multiple short-duration and high-voltage electrical pulses to release ablation energy, selectively causing myocardial cells to rupture and die. However, it has no obvious damaging effect on blood vessels, nerves, and tissues around the heart, such as the lungs, esophagus, and phrenic nerve.\n\nThis trial was designed based on the advantage of the characteristic that PFA does not damage the esophagus, confining the damage to the posterior half of the left atrium and the circumferential isthmus of the mitral valve. While improving the ablation success rate, it is possible to protect the function of the left atrium. This study aims to verify the superiority of the new rhythm control strategy in a large-scale population by launching a prospective randomized controlled trial.",[27,28,29,30,31],"Atrial Fibrillation (AF)","Atrial Fibrillation Ablation","Atrial Fibrillation Recurrent","Pulsed Field Ablation","Radiofrequency Catheter Ablation","RECRUITING","2026-05-24",{"date":35,"type":36},"2026-05-28","ACTUAL",{"date":38,"type":36},"2025-04-16",{"date":40,"type":21},"2028-11-30",{"name":42,"class":43},"China National Center for Cardiovascular Diseases","OTHER_GOV",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100425693","randomized-controlled-trial--ablation-strategy-for-paroxysmal-atrial-fibrillation---trigger-and-substrate-guided-wide-area-radiofrequency-ablation-compared-to-pulsed-field-ablation-pulmonary-vein-isolation-100425693","NCT04823299","Randomized Controlled Trial- Ablation Strategy for Paroxysmal Atrial Fibrillation - Trigger and Substrate Guided Wide Area Radiofrequency Ablation Compared to Pulsed Field Ablation Pulmonary Vein Isolation","AWARE-2 - Randomized Controlled Trial Ablation Strategy for Paroxysmal Atrial Fibrillation - Trigger and Substrate Guided Wide Area Radiofrequency Ablation Compared to Pulsed Field Ablation Pulmonary Vein Isolation","AWARE-2","Inclusion Criteria:\n\n1. Age ≥18 years on the date of consent for the trial.\n2. Subjects must have paroxysmal AF with at least one episode of AF over the past 12 months (patients on antiarrhythmic medications do not need to satisfy this criterion).\n\n   At least one episode of AF documented on 12-lead ECG, Holter monitor, Trans-telephonic monitor (TTM) or Loop Recorder.\n3. Subjects must be able to provide informed consent.\n\nExclusion Criteria:\n\n1. Persistent and permanent AF.\n2. History of previous catheter or surgical ablation for AF, AFl, AT, Atrioventricular Nodal Reentrant Tachycardia (AVNRT), Atrioventricular Reentrant Tachycardia (AVRT).\n3. Documented AVNRT, AVRT, AT or Atrial Flutter prior to enrolment in the trial.\n4. Previous left atrial (LA) ablation or LA surgery.\n5. Previous pulmonary vein stenosis or pulmonary vein stent.\n6. Pre-existing hemi-diaphragmatic paralysis.\n7. Active intracardiac thrombus.\n8. Contraindication to systemic oral anticoagulation therapy\n9. Current immunosuppressant therapy (corticosteroids, biologic immunomodulators; such patients may be considered if they can safely discontinue immunosuppressants for three months prior to and for three months following catheter ablation).\n10. Reversible causes of AF (e.g., uncontrolled hyperthyroidism, within six months of cardiac surgery).\n11. Left ventricular ejection fraction \\\u003C35%.\n12. NYHA Class 4 heart failure.\n13. Hypertrophic cardiomyopathy\n14. Significant valve disease (moderate or severe mitral\u002Faortic stenosis or regurgitation).\n15. Patients with mechanical mitral prosthetic valves\n16. Known adverse reaction to adenosine.\n17. Chronic Kidney Disease ≥ Stage 4.\n18. Significant congenital heart disease (including atrial septal defects or pulmonary vein abnormalities; however, subjects with patent foramen ovale will not be excluded).\n19. Pregnant subjects.\n20. Cerebral ischemic event (stroke or transient ischemic attack) in the six months prior to consenting for the trial.\n21. History of thromboembolic events in the 6 months preceding enrollment.\n22. Currently participating or anticipated to participate in interventional clinical trials of drug, device or biologic agents that could affect the results of this trial.\n23. Primary pulmonary hypertension\n24. Rheumatic heart disease\n25. Thrombocytosis, thrombocytopenia and other hypercoagulable states\n26. Active systemic infection\n27. Patients with life expectancy less than 12 months.\n28. Unwilling or unable to comply fully with study procedures and follow-up.",{"count":54,"type":21},556,[24],"Atrial fibrillation (AF) is a common heart rhythm disorder affecting over a million people in North America and is associated with serious complications including stroke, heart failure, reduced quality of life, and premature death. Catheter ablation has been shown to be more effective than medications for controlling symptoms and reducing the risk of these complications; however, recurrence of AF after ablation remains a significant challenge, often due to incomplete or ineffective initial procedures. This clinical trial aims to determine whether a novel, patient-tailored ablation strategy can improve outcomes compared to the current standard-of-care approach. Participants will be randomly assigned to undergo either standard pulmonary vein isolation or a more individualized ablation procedure that identifies and targets patient-specific sources of AF. All participants will undergo the ablation procedure, receive continuous heart rhythm monitoring, and be followed over time to assess recurrence and safety outcomes.",[58,59,31],"Atrial Fibrillation","Catheter Ablation","2026-04-23",{"date":62,"type":36},"2026-04-29",{"date":64,"type":36},"2026-03-23",{"date":66,"type":21},"2030-03",{"name":68,"class":69},"Ottawa Heart Institute Research Corporation","OTHER",2,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100603840","electroporation-vs-radiofrequency-ablation-guided-by-3d-imaging-in-repeat-procedures-for-atrial-fibrillation-100603840","NCT07141745","Electroporation vs. Radiofrequency Ablation Guided by 3D Imaging in Repeat Procedures for Atrial Fibrillation","ERA-rePVI","Inclusion Criteria:\n\nDocumented recurrence of AF or atypical atrial flutter after prior PVI Eligibility for re-PVI\n\nExclusion Criteria:\n\nLeft ventricular ejection fraction \\\u003C 30% Left atrial volume index (LAVI) \\> 72 mL\u002Fm² Untreated hyperthyroidism Hypertrophic cardiomyopathy Severe valvular heart disease","85 Years",{"count":80,"type":21},250,[24],"This is a prospective, randomized clinical trial evaluating the efficacy and safety of two techniques for repeat catheter ablation in patients with recurrent atrial fibrillation (AF): thermal energy ablation (radiofrequency) and non-thermal electroporation (pulsed field ablation), both guided by 3D imaging systems.\n\nPatients undergoing repeat AF ablation will be randomly assigned to receive either thermal or electroporation ablation, performed according to standard hospital protocols. No additional invasive procedures are required. Following the ablation, participants will attend follow-up visits at 3, 6, and 12 months, including medical history review, physical examination, 12-lead ECG, and 24-hour Holter monitoring. Unscheduled ECG assessments will also be available if arrhythmia symptoms occur.\n\nAll study-related procedures are non-invasive and align with routine post-ablation care. Risks are limited to those typically associated with standard AF ablation procedures.\n\nThe main benefit of participation is close, structured follow-up by experienced electrophysiologists, allowing for early detection of arrhythmia recurrence and timely medical intervention when necessary.\n\nParticipant confidentiality and data protection will be ensured in accordance with GDPR regulations.",[27,84,31,30],"Ablation Techniques",[86,30,31,87],"Atrial fibrillation re-ablation","Atrial firbillation reccurence","2025-08-26",{"date":90,"type":36},"2025-08-27",{"date":92,"type":21},"2025-08-30",{"date":94,"type":21},"2028-10-01",{"name":96,"class":69},"Wroclaw Medical University",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":44},"100576925","pulsed-field-ablation-versus-radiofrequency-ablation-for-persistent-atrial-fibrillation-100576925","NCT06791629","Pulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation","Pulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation: A Randomized, Open-label, Non-inferior Study","PRAISE","Inclusion Criteria:\n\n* 18-80 years\n* Patients with non-valvular persistent atrial fibrillation undergoing their first catheter ablation (AF duration: 3 months to 3 years)\n* Left atrial diameter on parasternal long-axis view of echocardiogram \\\u003C 50 mm\n* Agree to be randomly assigned to the ablation strategy and able to follow up\n\nExclusion Criteria:\n\n* Atrial fibrillation due to reversible causes\n* LVEF \\\u003C 30%\n* Severe congenital heart disease\n* Severe liver or kidney dysfunction (eGFR \\\u003C 15, Child-Pugh grade 3), or history of dialysis\n* History of cardiac surgery, such as coronary artery bypass grafting, mechanical valve or prosthetic valve replacement\n* History of pacemaker implantation, left atrial appendage closure, or patent foramen ovale closure\n* Contraindications to oral anticoagulation\n* Contraindications to right or left heart catheterization\n* Pregnancy\n* Life expectancy \\\u003C 1 year (e.g., advanced malignancy, end-stage renal disease)\n* Currently enrolled in another trial evaluating medical devices or drugs\n* Other situations where the investigator determines the subject is unsuitable for the study",{"count":106,"type":21},700,[24],"This clinical trial aims to compare the efficacy and safety of pulsed field ablation and radiofrequency ablation to treat persistent atrial fibrillation in adults.\n\nParticipants will:\n\nUndergo pulsed field ablation or radiofrequency ablation. Keep follow-up for at least 12 months.",[110,31,30],"Persistent Atrial Fibrillation",[112,31,113],"persistent atrial fibrillation","pulsed field ablation","NOT_YET_RECRUITING","2025-01-23",{"date":117,"type":36},"2025-01-24",{"date":119,"type":21},"2025-02-15",{"date":121,"type":21},"2027-02-15",{"name":123,"class":69},"Beijing Anzhen Hospital"]